Last reviewed · How we verify
Eucrisa (CRISABOROLE)
Eucrisa works by blocking the phosphodiesterase 4 enzyme, which helps reduce inflammation in the skin.
Eucrisa (crisaborole) is a small molecule phosphodiesterase 4 inhibitor developed by Anacor Pharms Inc, currently owned by the same company. It was FDA approved in 2016 for the treatment of atopic dermatitis. Eucrisa works by inhibiting the phosphodiesterase 4 enzyme, which plays a role in inflammation. The commercial status of Eucrisa is patented, with no generic manufacturers available. Key safety considerations include the potential for skin irritation and allergic reactions.
At a glance
| Generic name | CRISABOROLE |
|---|---|
| Sponsor | Anacor Pharms Inc |
| Drug class | Phosphodiesterase 4 Inhibitor [EPC] |
| Target | Phosphodiesterase 4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2016 |
Mechanism of action
Crisaborole is phosphodiesterase (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
Approved indications
- Atopic dermatitis
Common side effects
- Application site pain
- Contact urticaria
- Allergic contact dermatitis
Key clinical trials
- Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema (PHASE4)
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eucrisa CI brief — competitive landscape report
- Eucrisa updates RSS · CI watch RSS
- Anacor Pharms Inc portfolio CI